FDA enforcement report lists recalls of compounded semaglutide, tirzepatide, NAD+ and sermorelin
Three compounding pharmacies are pulling GLP-1 formulations blended with added vitamins such as niacinamide and cyanocobalamin, alongside sterility concerns.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 16 09:22 ETSource: MedShadow Foundation
The wire
- 01The latest FDA recalls roundup covers compounded tirzepatide, semaglutide, tirzepatide-niacinamide, semaglutide-cyanocobalamin, NAD+, sermorelin acetate, Tri-Mix and Quad Mix products.
- 02Pharmacists and telehealth operators dispensing vitamin-blended GLP-1s should check affected lot numbers and expiration dates in the FDA enforcement report.
- 03The added-ingredient formulations are often used as a legal argument that a product is not an outright copy of a brand drug; recall classifications and any reported harm were not detailed.
From the source
Read at medshadow.orgFDA Recalls and Warnings: Sterility Issues With Compounded GLP-1s, Foreign Pills in Generic Reglan Bottles
Get the latest FDA updates on medication recalls, manufacturing violations, and quality concerns that could affect your prescriptions.
